DRW Securities’s GT Biopharma GTBP Stock Holding History

DRW Securities’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-142,380	Closed	-$83.5K	–	1411
2025 Q3	$83.5K	Buy	+142,380	New	+$213K	﹤0.01%	1196

Other funds holding GTBP

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CMP

Coston McIsaac & Partners Bar Harbor, Maine $443M AUM 6.68% 1-Year Est. Return

Caitlin John Brighton, Michigan $167M AUM 23.74% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

DRW Securities's GTBP Position: Q4 2025 in Review

DRW Securities sold out of GT Biopharma (GTBP) in Q4 2025, closing a stake of 142,380 shares — an estimated $83.5K sold.

DRW Securities first reported a position in GTBP in Q3 2025 and held it in 1 quarter. The position peaked at $83.5K in Q3 2025. 38 funds tracked by Wall St. Rank hold GTBP as of Q4 2025.

DRW Securities reported no remaining GT Biopharma position as of Q4 2025 after selling out during the quarter.
DRW Securities sold 142,380 GT Biopharma shares in Q4 2025, an estimated $83.5K.
DRW Securities first reported a position in GT Biopharma in Q3 2025 and held it in 1 quarter.
DRW Securities's GT Biopharma position peaked at $83.5K in Q3 2025.
38 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.